LCM
RLAY icon

Laurion Capital Management’s Relay Therapeutics RLAY Stock Holding History

Laurion Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,000
Closed -$599K – 664
2022
Q1 		$599K Hold
20,000
– – 0.01% 286
2021
Q4 		$614K Buy
+20,000
New +$632K 0.01% 397

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Laurion Capital Management's RLAY Position: Q2 2022 in Review

Laurion Capital Management sold out of Relay Therapeutics (RLAY) in Q2 2022, closing a stake of 20,000 shares — an estimated $599K sold.

Laurion Capital Management first reported a position in RLAY in Q4 2021 and held it in 2 quarters. The position peaked at $614K in Q4 2021. 148 funds tracked by Wall St. Rank hold RLAY as of Q2 2022.

  • Laurion Capital Management reported no remaining Relay Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Laurion Capital Management sold 20,000 Relay Therapeutics shares in Q2 2022, an estimated $599K.
  • Laurion Capital Management first reported a position in Relay Therapeutics in Q4 2021 and held it in 2 quarters.
  • Laurion Capital Management's Relay Therapeutics position peaked at $614K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.